Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
AssigneeStichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
InventorsLiqin Wang, Rodrigo Leite De Oliveira, Rene Bernards
Life of this patent
Estimating the term…
Abstract
The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.
Claims7
A method of treating a subject with melanoma characterized in that the melanoma is a BRAF-mutation or a NRAS-mutation harboring melanoma, the method comprising:
- a) Treating said subject with a therapeutically acceptable amount of a MAPK pathway inhibitor, wherein the treatment with the MAPK pathway inhibitor does not involve a simultaneous treatment with an HDACi;
- b) Discontinuing treating the subject with said therapeutically acceptable amount of the MAPK pathway inhibitor when the melanoma has acquired resistance to the MAPK pathway inhibitor;
- c) Treating said subject with a therapeutically acceptable amount of a histone deacytylase inhibitor (HDACi) after treatment with MAPK pathway inhibitor is discontinued in step b).
Dependencies are inferred from the claim text.